We Deliver First-in-Class Therapies
We are an early-stage pharmaceutical company creating first-in-class therapies designed to boost expression of therapeutic genes in diseased cells.
RNAa (RNA activation) is a platform technology to selectively turn genes on by using short duplex RNA known as small activating RNA (saRNA).
RNAa is one of the few technologies that can stimulate production of endogenous targeted genes.
The Push for the Next
Generation of Therapeutics
Ractigen has a diverse pipeline covering previously undruggable diseases and monogenic disorders including oncology, CNS, and liver-related indications.
The pipeline explores the boundaries of our technology and pushes for the next generation of RNAa therapeutics.
Meet Our Team
We are led by a cohesive team of scientists and professionals with a broad background in RNA research and drug development including the inventors of RNAa technology, nucleic acid chemists, biotech entrepreneurs and experts in drug discovery.
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
Ractigen Therapeutics today announced the closing…
Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital
Ractigen Therapeutics, a leading company in the saRNA drug space…
CB Insights lists Ractigen as one of the Top RNA biotech companies in China
CB Insights China published a top list of RNA biotech companies in China…
Delegation from Nantong University Medical School visits Ractigen
Today, a 5-member delegation, led by the dean Professor Fei Sun…
Scientists from Ractigen and KRIBB publish new study on saRNA-guided activation of VHL gene in renal cell carcinoma
Today, an article entitled “Small activating RNA induced…
Ractigen Therapeutics CSO Dr. Robert Place delivers a keynote speech at the 6th RNAi China conference
The 6th RNAi China conference was held on October 10th and 11th…